acute coronary syndrome and
peripheral arterial disease
thrombus during vascular
interventions is a key for therapy
Innovative,
independent,
close to the patient
We are a biotech company that independently develops innovative drugs and diagnostics for personalised treatment of cardiovascular diseases. We have a unique product pipeline that we are consistently moving into clinical trials. Our lead compound has been successfully tested in two Phase II studies.
advancecor therapeutic agents for prevention and treatment of acute arterial thrombosis
advancecor therapeutic agents for prevention and treatment of acute arterial thrombosis
Revacept
Therapeutic agent for the prevention and treatment of acute arterial thrombosis.
GPVI-inhibitory
antibodies
Preventing the activation of blood platelets, protecting against heart attacks and strokes.
Our
Pipeline
We have a broadly diversified pipeline of various drugs in preclinical development through to phase II. Indications include stroke, PAD, CHD and inflammatory diseases such as major diseases and rheumatoid arthritis. For details please click here:
Our service for you
Expert GLP Measurements
and Biomedical Services
You are looking for a service partner for the development of GLP-based measurement procedures? advanceCOR is approved for ELISA-based measurement procedures and different platelet assays according to the quality criteria of Good Laboratory Practice (GLP). For our customers we take over, for example, the investigation of pharmacokinetics in the context of preclinical or clinical projects. We also carry out the determination of antibodies in blood samples and other fluids on behalf of our clients.
Our Investors
